Login to Your Account



Earnings Roundup

Dendreon CEO Not Happy with Sales of Provenge

By Peter Winter
BioWorld Insight Editor

Wednesday, August 8, 2012

Commenting on his company's second-quarter financial results in an investor call, Dendreon Corp. CEO John Johnson said, "I'm not satisfied with the commercial performance of Provenge and believe that more men with advanced prostate cancer should be benefiting from the product."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription